Cargando…

A rare case of prostate neuroendocrine tumor: A case report

Small cell prostate neuroendocrine carcinoma (SCPC) is a rare and highly aggressive malignant tumor. We present a case of a 52-year-old Iranian man, presenting with complaints of occasional gross hematuria and perineal pain for 6 months. PSA was 0.8 ng/ml. A digital rectal examination found a huge a...

Descripción completa

Detalles Bibliográficos
Autores principales: Teh, Shunxing, Inn, Fam Xeng, Rizuana, Iqbal Hussain, WM, Wan Muhaizan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574441/
https://www.ncbi.nlm.nih.gov/pubmed/36263212
http://dx.doi.org/10.3389/fonc.2022.1009146
_version_ 1784811106894610432
author Teh, Shunxing
Inn, Fam Xeng
Rizuana, Iqbal Hussain
WM, Wan Muhaizan
author_facet Teh, Shunxing
Inn, Fam Xeng
Rizuana, Iqbal Hussain
WM, Wan Muhaizan
author_sort Teh, Shunxing
collection PubMed
description Small cell prostate neuroendocrine carcinoma (SCPC) is a rare and highly aggressive malignant tumor. We present a case of a 52-year-old Iranian man, presenting with complaints of occasional gross hematuria and perineal pain for 6 months. PSA was 0.8 ng/ml. A digital rectal examination found a huge and hard prostate mass. He underwent a transrectal ultrasound-guided (TRUS) biopsy of the prostate. Histopathology showed high-grade small cell neuroendocrine carcinoma. Immunohistochemical markers were positive for synaptophysin with a Ki67 index of almost 100%. However, CD56 and chromogranin A markers were negative. Magnetic resonance imaging (MRI) of the prostate showed a prostate mass with invasion to the rectum, while contrast-enhanced computed tomography of the thorax, abdomen, and pelvis (CT TAP) ruled out metastasis. A multidisciplinary team discussion was carried out, and a decision was made for concurrent chemotherapy and radiation (cisplatin and etoposide for 4 cycles and 70 Gy, 35 fractions). There is a lack of consensus on the management of SCPC. The main modality of management in advanced (stage IV) disease is chemotherapy. It is a highly aggressive tumor with a poor prognosis and is not responsive to hormonal therapy.
format Online
Article
Text
id pubmed-9574441
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95744412022-10-18 A rare case of prostate neuroendocrine tumor: A case report Teh, Shunxing Inn, Fam Xeng Rizuana, Iqbal Hussain WM, Wan Muhaizan Front Oncol Oncology Small cell prostate neuroendocrine carcinoma (SCPC) is a rare and highly aggressive malignant tumor. We present a case of a 52-year-old Iranian man, presenting with complaints of occasional gross hematuria and perineal pain for 6 months. PSA was 0.8 ng/ml. A digital rectal examination found a huge and hard prostate mass. He underwent a transrectal ultrasound-guided (TRUS) biopsy of the prostate. Histopathology showed high-grade small cell neuroendocrine carcinoma. Immunohistochemical markers were positive for synaptophysin with a Ki67 index of almost 100%. However, CD56 and chromogranin A markers were negative. Magnetic resonance imaging (MRI) of the prostate showed a prostate mass with invasion to the rectum, while contrast-enhanced computed tomography of the thorax, abdomen, and pelvis (CT TAP) ruled out metastasis. A multidisciplinary team discussion was carried out, and a decision was made for concurrent chemotherapy and radiation (cisplatin and etoposide for 4 cycles and 70 Gy, 35 fractions). There is a lack of consensus on the management of SCPC. The main modality of management in advanced (stage IV) disease is chemotherapy. It is a highly aggressive tumor with a poor prognosis and is not responsive to hormonal therapy. Frontiers Media S.A. 2022-10-03 /pmc/articles/PMC9574441/ /pubmed/36263212 http://dx.doi.org/10.3389/fonc.2022.1009146 Text en Copyright © 2022 Teh, Inn, Rizuana and WM https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Teh, Shunxing
Inn, Fam Xeng
Rizuana, Iqbal Hussain
WM, Wan Muhaizan
A rare case of prostate neuroendocrine tumor: A case report
title A rare case of prostate neuroendocrine tumor: A case report
title_full A rare case of prostate neuroendocrine tumor: A case report
title_fullStr A rare case of prostate neuroendocrine tumor: A case report
title_full_unstemmed A rare case of prostate neuroendocrine tumor: A case report
title_short A rare case of prostate neuroendocrine tumor: A case report
title_sort rare case of prostate neuroendocrine tumor: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574441/
https://www.ncbi.nlm.nih.gov/pubmed/36263212
http://dx.doi.org/10.3389/fonc.2022.1009146
work_keys_str_mv AT tehshunxing ararecaseofprostateneuroendocrinetumoracasereport
AT innfamxeng ararecaseofprostateneuroendocrinetumoracasereport
AT rizuanaiqbalhussain ararecaseofprostateneuroendocrinetumoracasereport
AT wmwanmuhaizan ararecaseofprostateneuroendocrinetumoracasereport
AT tehshunxing rarecaseofprostateneuroendocrinetumoracasereport
AT innfamxeng rarecaseofprostateneuroendocrinetumoracasereport
AT rizuanaiqbalhussain rarecaseofprostateneuroendocrinetumoracasereport
AT wmwanmuhaizan rarecaseofprostateneuroendocrinetumoracasereport